PCRX - NASDAQ
Pacira BioSciences, Inc.
$22.32
+0.31%Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
At a Glance
Live SnapshotPacira BioSciences, Inc. Management Team
Mr. David M. Stack
Advisor
Compensation
$727,378
Ms. Kristen Williams Esq., J.D.
Chief Administrative Officer & Secretary
Compensation
$1,002,432
Mr. Frank D. Lee
Chief Executive Officer & Director
Compensation
$3,152,376
Mr. Shawn M. Cross
Chief Financial Officer
Compensation
$566,787
Mr. Anthony Molloy III, Esq.
Chief Legal & Compliance Officer
Compensation
$581,410
Mr. Christopher C. Young
Chief Manufacturing Officer
Dr. Jonathan Slonin M.D.
Chief Medical Officer
Compensation
$1,030,566
Mr. Charles A. Reinhart III, CPA, M.B.A.
Executive Officer
Compensation
$1,058,674
Ms. Susan Mesco
Head of Investor Relations
Ms. Lauren Bullaro Riker
Principal Accounting Officer & Senior Vice President of Finance
Compensation
$1,949,982
Pacira BioSciences, Inc. Insider Positioning
During the last 12 months, insiders have sold $2.35M worth of PCRX shares, with no buying activity reported.
3 Months
0
0.00
25.9K
642.36K
-642K
-$642K
3-6 Months
0
0.00
43.6K
1.01M
-1.0M
-$1.01M
6-9 Months
0
0.00
22.7K
504.83K
-505K
-$505K
9-12 Months
0
0.00
7.6K
187.22K
-187K
-$187K
Top Buyers
No buying activity
Top Sellers
Cross Shawn
Officer: Chief Financial Officer
$1.59M
Williams Kristen
Officer: Chief Administrative Officer
$270K
Slonin Jonathan
Officer: Chief Medical Officer
$177K
Riker Lauren
Officer: Senior Vice President, Finance
$118K
Bigal Marcelo
Director
$116K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $2.35M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
PCRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | April 29, 2025 | June 10, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 22, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 21, 2023 | April 21, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | June 08, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 24, 2020 | June 08, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 22, 2019 | June 04, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 27, 2018 | June 12, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 21, 2017 | June 13, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 21, 2016 | June 14, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.